SEATTLE, WASHINGTON--(Marketwire - May 29, 2012) - VentriPoint Diagnostics Ltd. ("VentriPoint") (TSX VENTURE:VPT) (OTCQX:VPTDF) exhibited its VMS™ heart analysis system at the Annual Meeting of the Association of European Paediatric Cardiologists (AEPC) from May 23-26 in Istanbul, Turkey.

The VentriPoint VMS™ heart analysis system was featured in a presentation to over 300 pediatric cardiologists entitled "Echocardiography: From Visible to Invisible" and given by Dr. Jan Marek, Head of the Echocardiography and Prenatal Cardiology at Great Ormond Street Hospital for Children and Senior Lecturer of Institute of Child's Health at University College London and Chair of the Imaging Working Group of the AEPC and Co-organizer of European educational program in Paediatric Echocardiography under the AEPC and European Society of Cardiology (ESC)/ European Association of Echocardiography (EAE).

"Today we presented data showing the VMS™ gave consistent and accurate information on the volume and function of the right heart, while 3D echocardiology significantly underestimates the volume and function of the right heart, " said Dr. Marek.

VentriPoint is initially focusing its technology on quantifying 2D images of the right ventricle (RV). Using 2D ultrasound images, the VMS™ performs knowledge-based reconstruction to create 3D images of the right ventricle and calculates accurate volumetric and functional measurements. Clinical studies have shown that these VMS™ measurements are equivalent to those using Magnetic Resonance Imaging (MRI), the current standard of care.

"It is always rewarding to have our users tell their colleagues about the virtues of the VMS™," said Dr. George Adams, President and CEO of VentriPoint, "The AEPC is a good conference to demonstrate the VMS™ to a focused group of pediatric cardiologists, who recognize the need for better and more efficient RV imaging and analysis."

About VentriPoint Diagnostics Ltd.

VentriPoint has created a diagnostic ultrasound tool to monitor patients with heart disease, a leading cause of death in developed countries. Management believes the VMS™ is the first cost-effective and accurate diagnostic tool for measuring right ventricle heart function. Congenital heart disease is the first application in a suite of applications for all major heart diseases including pulmonary hypertension, cardiovascular disease and heart failure, which management believes has a multibillion-dollar market potential. Canada and Europe (CE Mark) have granted approval for the sale of VentriPoint's VMS™ heart analysis system and VentriPoint is pursuing the US-FDA approval through the 510(k) process.

FORWARD-LOOKING STATEMENTS: The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address VentriPoint's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Corporation's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. These forward-looking statements are made as of the date of this press release and, other than as required by applicable securities laws, the Corporation does not assume any obligation to update or revise them to reflect new events or circumstances. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.